Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Lymphoma
  Free Subscription

Articles published in
Cancer
    March 2026
  1. DAVIES GA, Prica A, Ante Z, Liu N, et al
    Secondary primary malignancies in indolent non-Hodgkin lymphoma patients receiving frontline bendamustine-rituximab.
    Cancer. 2026;132:e70327.
    >> Share

    February 2026
  2. MANTZ L, Johnson PC, Lei M, Newcomb RA, et al
    Exploratory association of muscle and adipose tissue indices with clinical outcomes in aggressive lymphomas.
    Cancer. 2026;132:e70313.
    >> Share

  3. TANG L, Cai D, Yan X, Mo W, et al
    Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis.
    Cancer. 2026;132:e70317.
    >> Share

    January 2026
  4. YILMAZ U, Dal MS, Ulas T, Atesoglu EB, et al
    Exploring an independent association between rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone dose intensity and clinical outcomes in large B-cell lymphoma: Analyses of subsequent endpoints following a complete response in a real-world
    Cancer. 2026;132:e70248.
    >> Share

  5. KONOPLEVA M, Pemmaraju N, Sweet KL, Stein AS, et al
    Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm.
    Cancer. 2026;132:e70243.
    >> Share

  6. ZHAO W, Li L, Fu X, Chang Y, et al
    A first-line regimen combining Bruton's tyrosine kinase and programmed cell death protein-1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma.
    Cancer. 2026;132:e70247.
    >> Share

    December 2025
  7. SHI W, Ren Y, Liu S, Liu Y, et al
    Clinical characteristics and survival outcomes of thymic mucosa-associated lymphoid tissue lymphoma: A multicenter analysis of 82 patients.
    Cancer. 2025;131:e70183.
    >> Share

    September 2025
  8. TAN S, He H, Ni J, Guo Y, et al
    Meta-analysis evaluating the efficacy and safety of various Bruton tyrosine kinase (BTK) inhibitors for central nervous system lymphoma: Novel covalent BTK inhibitors, except for ibrutinib, also demonstrate good efficacy in the treatment of primary ce
    Cancer. 2025;131:e70083.
    >> Share

  9. NIERENGARTEN MB
    Safety and promising efficacy with enhanced CAR T-cell therapy for lymphoma.
    Cancer. 2025;131:e70035.
    >> Share

    June 2025

  10. Correction to "Surveillance imaging during first remission in follicular lymphoma does not impact overall survival".
    Cancer. 2025;131:e35934.
    >> Share

  11. NIERENGARTEN MB
    Ibrutinib plus venetoclax improves progression-free survival in refractory or relapsed mantle cell lymphoma.
    Cancer. 2025;131:e35899.
    >> Share


  12. Correction to "Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study".
    Cancer. 2025;131:e35933.
    >> Share

    March 2025
  13. RAYCHAUDHURI S, McLaughlin E, Pennell ML, Stefanick M, et al
    The relationship between cardiometabolic abnormalities and mortality in the Women's Health Initiative: A comparison of associations among women with cancer to women without cancer.
    Cancer. 2025;131:e35804.
    >> Share

  14. JIMENEZ MUNARRIZ BE, Khan S, Li Y, Ghazali N, et al
    Update advances in anaplastic lymphoma kinase-positive non-small cell lung cancer treatment.
    Cancer. 2025;131 Suppl 1:e35786.
    >> Share

    January 2025
  15. YIN X, He Q, Liu D, Xie L, et al
    Zanubrutinib plus R-CHOP for the treatment of newly diagnosed double-expressor lymphoma: A phase 2 clinical study.
    Cancer. 2025;131:e35697.
    >> Share

  16. GAO Y, Huang Y, Zhang Q, Yang H, et al
    Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial.
    Cancer. 2025;131:e35672.
    >> Share

    November 2024
  17. HANZLIK E, Sabin ND, Yoshida T, Delaney A, et al
    Sexual dysfunction among long-term survivors of Hodgkin lymphoma.
    Cancer. 2024 Nov 7. doi: 10.1002/cncr.35637.
    >> Share

  18. LI Z, Li X, Li S, Tao R, et al
    Preclinical evaluation and phase 1 study of the PI3Kalpha/delta inhibitor TQ-B3525 in Chinese patients with advanced cancers.
    Cancer. 2024;130:3686-3698.
    >> Share

    October 2024
  19. NIERENGARTEN MB
    Multitargeted therapy is safe and leads to durable remission of DLBCL.
    Cancer. 2024;130:3238.
    >> Share

    August 2024
  20. ZENG C, Wei Z, Huang J, Zhu J, et al
    Effect of body mass index on the prognosis of children and adolescents with high-grade mature B-cell non-Hodgkin lymphoma.
    Cancer. 2024 Aug 22. doi: 10.1002/cncr.35536.
    >> Share

    June 2024
  21. HSU YT, Wu SJ, Kao HW, Hsiao SY, et al
    Glofitamab as a salvage treatment for B-cell lymphomas in the real world: A multicenter study in Taiwan.
    Cancer. 2024;130:1972-1981.
    >> Share

    May 2024
  22. LI ZH, Zhang MY, Federico M, Civallero M, et al
    Early histological transformation of follicular lymphoma to diffuse large B-cell lymphoma indicating adverse survival: A population-based analysis and validation.
    Cancer. 2024 May 29. doi: 10.1002/cncr.35378.
    >> Share

    April 2024
  23. NIERENGARTEN MB
    Golidocitinib favorable for relapsed/refractory T-cell lymphoma.
    Cancer. 2024;130:1191-1192.
    >> Share

  24. LI A, Yi H, Deng S, Ruan M, et al
    The genetic landscape of histologically transformed marginal zone lymphomas.
    Cancer. 2024;130:1246-1256.
    >> Share

  25. GIRI S, Harmon C, Landier W, Chen Y, et al
    Body composition and late-occurring chronic health conditions after autologous stem cell transplantation for lymphoma.
    Cancer. 2024 Apr 5. doi: 10.1002/cncr.35298.
    >> Share

    February 2024
  26. WU S, Rhee JW, Iukuridze A, Bosworth A, et al
    Coronary artery calcium and cardiovascular outcomes in patients with lymphoma undergoing autologous hematopoietic cell transplantation.
    Cancer. 2024 Feb 15. doi: 10.1002/cncr.35252.
    >> Share

  27. TZANKOV A, Tatarczuch M
    Time to Be Launched 1 auXiliary Risk strat1fier in marginal zone lymphoma transformation: TBL1XR1.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35246.
    >> Share

    January 2024
  28. SEDETA E, Jemal A, Nisotel L, Sung H, et al
    Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt.
    Cancer. 2024 Jan 20. doi: 10.1002/cncr.35214.
    >> Share

    December 2023
  29. DAI L, Chen H, Tan Q, Wang Y, et al
    Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray.
    Cancer. 2023 Dec 22. doi: 10.1002/cncr.35158.
    >> Share

  30. CHU Y, Liu Y, Yu Z, Zhan L, et al
    Maintenance and consolidation strategies for patients with untreated advanced follicular lymphoma: A systematic review and network meta-analysis of randomized trials.
    Cancer. 2023 Dec 2. doi: 10.1002/cncr.35137.
    >> Share

    November 2023
  31. GORDON MJ, Feng L, Strati P, Lee HJ, et al
    Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
    Cancer. 2023 Nov 20. doi: 10.1002/cncr.35114.
    >> Share

  32. NIERENGARTEN MB
    New potential therapy for relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Cancer. 2023;129:3356.
    >> Share

  33. WADHWA A, Lim S, Dai C, Daniels G, et al
    Assessment of longitudinal changes in body composition of children with lymphoma and rhabdomyosarcoma.
    Cancer. 2023;129:3457-3465.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016